Table 1.
Clinicopathological characteristics of included high-grade serous ovarian cancer patients and subgroups thereof.
| Subgroups Based on Collected Samples * | ||||
|---|---|---|---|---|
| All Patients (n = 34) |
Patients with Plasma Collected (n = 24) |
Patients with Ascites Collected (n = 32) | Patients with Both Plasma and Ascites Collected (n = 22) † | |
| Age (years) | ||||
| Median (IQR) | 62.5 (58–68) | 62.5 (56–69) | 63 (59–69) | 63 (58–70) |
| BMI (kg/m2) | ||||
| Median (IQR) | 24 (22–27) | 24 (22–27) | 25 (22–28) | 24 (22–27) |
| FIGO stage | ||||
| II | 2 (5.9%) | 1 (4.2%) | 2 (6.3%) | 1 (4.5%) |
| III | 24 (70.6%) | 16 (66.7%) | 22 (68.8%) | 14 (63.6%) |
| IV | 8 (23.5%) | 7 (29.2%) | 8 (25.0%) | 7 (31.8%) |
| Primary treatment completed | ||||
| Yes | 26 (76.5%) | 20 (83.3%) | 24 (75.0%) | 18 (81.8%) |
| No | 8 (23.5%) | 4 (16.7%) | 8 (25.0%) | 4 (18.2%) |
BMI: body mass index; FIGO: International Federation of Gynecology and Obstetrics; IQR: interquartile range. Percentages may not total to 100% due to rounding. * Samples from remaining patients were missing for logistic reasons. † Also referred to as “overlapping patients”.